Andrea M Harriott
Overview
Explore the profile of Andrea M Harriott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lipton R, Gandhi P, Tassorelli C, Reuter U, Harriott A, Holle-Lee D, et al.
Neurology
. 2024 Dec;
104(2):e210212.
PMID: 39715475
Background And Objectives: Three phase 3 trials demonstrated the efficacy and safety of atogepant in episodic migraine (EM) and chronic migraine (CM) across 12-week treatment periods. This analysis evaluates improvements...
2.
Harriott A, Kaya M, Ayata C
J Headache Pain
. 2024 Oct;
25(1):183.
PMID: 39434018
No abstract available.
3.
Harriott A, Kaya M, Ayata C
J Headache Pain
. 2024 Sep;
25(1):152.
PMID: 39289629
Background: Migraine is among the most prevalent and burdensome neurological disorders in the United States based on disability-adjusted life years. Cortical spreading depolarization (SD) is the most likely electrophysiological cause...
4.
Lipton R, Harriott A, Ma J, Smith J, Stokes J, Gandhi P, et al.
Neurology
. 2024 Aug;
103(6):e209745.
PMID: 39197113
Background And Objectives: Ubrogepant is a calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine. The PRODROME trial previously demonstrated that ubrogepant treatment during prodrome prevents the...
5.
Roy A, Sreekrishnan A, Camargo Faye E, Silverman S, Zachrison K, Harriott A, et al.
Neurol Clin Pract
. 2023 Oct;
13(6):e200209.
PMID: 37829551
Background And Objectives: Evaluation of transient ischemic attack/nondisabling ischemic strokes (TIA/NDS) in the emergency department (ED) contributes to capacity issues and increasing health care expenditures, especially high-cost duplicative imaging. Methods:...
6.
Blumenfeld A, Rabany L, Ironi A, Stark-Inbar A, Harris D, Halker Singh R, et al.
Pain Manag
. 2023 Aug;
13(8):425-432.
PMID: 37615080
To evaluate the onset, magnitude and persistence of efficacy of remote electrical neuromodulation (REN) compared with placebo for the preventive treatment of migraine. Analysis was conducted on data from a...
7.
Harriott A, Waruinge A, Appiah-Danquah V, Berhanu L, Morais A, Ayata C
J Headache Pain
. 2023 Jul;
24(1):85.
PMID: 37464297
Background: Migraine is more prevalent in females, raising the possibility that sex and gonadal hormones modulate migraine. We recently demonstrated that minimally invasive optogenetic spreading depolarization (opto-SD) elicits robust periorbital...
8.
Morais A, Qin T, Ayata C, Harriott A
Pain
. 2023 Jun;
164(11):2564-2571.
PMID: 37318029
We investigated the efficacy of inhibiting persistent Na + currents (I NaP ) in acute rodent models of migraine with aura. Cortical spreading depression (SD) is a slow wave of...
9.
Kudo C, Harriott A, Moskowitz M, Waeber C, Ayata C
J Headache Pain
. 2023 May;
24(1):62.
PMID: 37237336
Background And Aims: Cortical spreading depression (CSD), a transient neuronal and glial depolarization that propagates slowly across the cerebral cortex, is the putative electrophysiological event underlying migraine aura and a...
10.
Purdue-Smithe A, Stuart J, Farland L, Kang J, Harriott A, Rich-Edwards J, et al.
Neurology
. 2023 Jan;
100(14):e1464-e1473.
PMID: 36657989
Background And Objective: Migraine is a highly prevalent neurovascular disorder among reproductive-aged women. Whether migraine history and migraine phenotype might serve as clinically useful markers of obstetric risk is not...